🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Allergan, Adamas settle patent lawsuit with Amneal

Published 08/31/2016, 10:17 AM
Updated 08/31/2016, 10:20 AM
© Reuters. Traders work at the post where Allergan stock is traded on the floor of the NYSE
AGN_pa
-

(Reuters) - Allergan (NYSE:AGN_pa) Plc said it and Adamas Pharmaceuticals Inc settled a patent infringement lawsuit with Amneal Pharmaceuticals over their Alzheimer's drug.

Allergan said its Forest Labs unit and Adamas had filed a lawsuit against privately owned Amneal, which was seeking regulatory approval for generic versions of Namzaric.

The drug, which has been licensed to Forest by Adamas, had U.S. sales of $12.8 million for the quarter ended June 30.

Under the settlement terms, Forest and Adamas will grant Amneal a license to market generic versions of Namzaric from January 1, 2025.

Other terms of the settlement were not disclosed.

© Reuters. Traders work at the post where Allergan stock is traded on the floor of the NYSE

Allergan and Adamas have also sued Amerigen Pharmaceuticals, which seeks to market generic versions of the drug.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.